Entero Therapeutics (ENTO) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Document And Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-37853
Entity Registrant Name	First Wave BioPharma, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4993860
Entity Address, Address Line One	777 Yamato Road, Suite 502
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	561
Local Phone Number	589-7020
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	FWBI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,795,404
Entity Central Index Key	0001604191
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 1,657,013	$ 8,248,684
Other receivables	191,984
Prepaid expenses	561,459	1,176,268
Deferred offering costs	138,684
Total Current Assets	2,549,140	9,424,952
Property, equipment, and leasehold improvements, net	51,157	73,110
Other Assets:
Goodwill	1,714,787	1,911,705
Restricted cash	21,505
Operating lease right-of-use assets	274,516	336,197
Deposits	34,298	44,012
Total Other Assets	2,045,106	2,291,914
Total Assets	4,645,403	11,789,976
Current Liabilities:
Accounts payable	3,582,988	2,707,731
Accrued expenses	272,268	393,253
Accrued dividend payable	763,556	465,361
Note payable		641,236
Operating lease liabilities	64,397	77,989
Payable related to acquisition - current	2,000,000	8,000,000
Other current liabilities	10,951	14,818
Total Current Liabilities	6,694,160	12,300,388
Non-current operating lease liabilities	231,292	311,138
Payable related to acquisition - long term		7,000,000
Total Liabilities	6,925,452	19,611,526
Commitments and Contingencies
Stockholders' Deficit:
Common stock - Par value $0.0001 per share; 50,000,000 shares authorized; 2,307,008 and 495,194 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	231	50
Additional paid-in capital	163,722,141	147,306,582
Accumulated deficit	(164,547,700)	(153,904,047)
Accumulated other comprehensive loss	(1,454,721)	(1,224,135)
Total Stockholders' Deficit	(2,280,049)	(7,821,550)
Total Liabilities and Stockholders' Deficit	4,645,403	11,789,976
Series B preferred stock
Stockholders' Deficit:
Preferred stock	0	0
Series C preferred stock
Stockholders' Deficit:
Preferred stock	0	0
Series D preferred stock
Stockholders' Deficit:
Preferred stock	0	0
Series E preferred stock
Stockholders' Deficit:
Preferred stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Feb. 13, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	25,000,000	50,000,000
Common stock, shares issued (in shares)	2,307,008		495,194
Common stock, shares outstanding (in shares)	2,307,008		495,194
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred stock, shares designated (in shares)	10,000,000
Series B preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Preferred stock, shares designated (in shares)	5,194.805195		5,194.805195
Preferred stock, shares issued (in shares)	631.34		662.25
Preferred stock, shares outstanding (in shares)	631.34		662.25
Series C preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Preferred stock, shares designated (in shares)	57,000		57,000
Preferred stock, shares issued (in shares)	0		0
Preferred stock, shares outstanding (in shares)	0		0
Series D preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Preferred stock, shares designated (in shares)	150		150
Preferred stock, shares issued (in shares)	0		0
Preferred stock, shares outstanding (in shares)	0		0
Series E preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Preferred stock, shares designated (in shares)	150		150
Preferred stock, shares issued (in shares)	0		0
Preferred stock, shares outstanding (in shares)	0		0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development expenses	$ 791,067	$ 3,052,791	$ 8,674,480	$ 11,216,616
Research and development (recovery) expenses- intellectual property acquired	(8,085,045)	21,325,527	(8,085,045)	21,325,527
General and administrative expenses	2,904,448	6,021,160	9,808,960	15,347,764
Total operating (recovery) expenses	(4,389,530)	30,399,478	10,398,395	47,889,907
Income (loss) from operations	4,389,530	(30,399,478)	(10,398,395)	(47,889,907)
Other income (expenses):
Interest expense	(863)	(742)	(9,686)	(8,840)
Interest income	2,664		3,729
Other (expense) income		(568)	(239,301)	1,032
Change in fair value of liability				532,353
Total other income (expenses)	1,801	(1,310)	(245,258)	524,545
Net income (loss)	4,391,331	(30,400,788)	(10,643,653)	(47,365,362)
Other comprehensive income (loss):
Foreign currency translation adjustment	(35,235)	(41,604)	(230,586)	(154,561)
Total comprehensive income (loss)	4,356,096	(30,442,392)	(10,874,239)	(47,519,923)
Net income (loss)	4,391,331	(30,400,788)	(10,643,653)	(47,365,362)
Deemed dividend on preferred stock issuances				(4,507,125)
Deemed dividend on preferred stock exchanges				(21,008,253)
Deemed dividend on warrant modifications	(47,300)		(47,300)
Preferred stock dividends	(110,278)	(118,089)	(298,195)	(349,132)
Net income (loss) applicable to common shareholders	$ 4,233,753	$ (30,518,877)	$ (10,989,148)	$ (73,229,872)
Basic weighted average shares outstanding	1,601,415	311,411	952,794	253,118
Diluted weighted average shares outstanding	1,625,736	311,411	952,794	253,118
Net income (loss) per share - basic	$ 2.64	$ (98)	$ (11.53)	$ (289.31)
Net income (loss) per share - diluted	$ 2.60	$ (98)	$ (11.53)	$ (289.31)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (unaudited) - USD ($)	Common Stock, Pre-funded Warrants, and Cash Warrants [Member] Common Stock	Common Stock, Pre-funded Warrants, and Cash Warrants [Member] Additional Paid-in Capital	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]	Issuance of Series D Preferred Stock And Warrants Convertible preferred stock Series D Convertible Preferred Stock	Issuance of Series D Preferred Stock And Warrants Common Stock	Issuance of Series D Preferred Stock And Warrants Additional Paid-in Capital	Issuance of Series D Preferred Stock And Warrants	Issuance Of Series E Preferred Stock And Warrants Convertible preferred stock Series E Convertible Preferred Stock	Issuance Of Series E Preferred Stock And Warrants Common Stock	Issuance Of Series E Preferred Stock And Warrants Additional Paid-in Capital	Issuance Of Series E Preferred Stock And Warrants	Conversion of Series B Preferred Shares Into Common Stock Convertible preferred stock Series B Convertible Preferred Stock	Conversion of Series B Preferred Shares Into Common Stock Common Stock	Convertible preferred stock Series B Convertible Preferred Stock	Convertible preferred stock Series C Convertible Preferred Stock	Convertible preferred stock Series E Convertible Preferred Stock	Convertible preferred stock Series D Convertible Preferred Stock	Common Stock	Additional Paid-in Capital Series E Convertible Preferred Stock	Additional Paid-in Capital Series D Convertible Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Series E Convertible Preferred Stock	Series D Convertible Preferred Stock	Total
Balance at the beginning (in shares) at Dec. 31, 2020														2,774				103,834
Balance at the beginning at Dec. 31, 2020																		$ 10			$ 93,838,041	$ (95,366,198)	$ (1,112,546)			$ (2,640,693)
Issuance of Series C preferred stock and warrants for cash, net of offering costs (in shares)															10,667	10,667	10,667
Issuance of Series C preferred stock and warrants for cash, net of offering costs															$ 1	$ 1	$ 1				7,105,167					7,105,168
Beneficial conversion feature of Series C preferred stock																					4,507,125					4,507,125
Issuance of Series C preferred stock upon exchange of Series B preferred stock (in shares)														(1,839)	19,140	19,140	19,140
Issuance of Series C preferred stock upon exchange of Series B preferred stock															$ 1	$ 1	$ 1				(1,431)					(1,430)
Warrants issued in connection with exchange of Series B preferred stock into Series C preferred stock																					21,009,683					21,009,683
Deemed dividend of Series C preferred stock																					(4,507,125)					(4,507,125)
Common stock issued upon conversion of Series B preferred stock (in shares)														(259)				8,609
Common stock issued upon conversion of Series B preferred stock																		$ 1			(1)
Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)															(33,097)	(33,097)	(33,097)
Issuance of Series C preferred stock to for license acquired (in shares)															3,290	3,290	3,290
Issuance of Series C preferred stock to for license acquired															$ 1	$ 1	$ 1				2,467,648					2,467,649
Deemed dividend on preferred stock issuances																										(4,507,125)
Deemed dividend related to exchange of Series B preferred stock																					(21,008,253)					(21,008,253)
Exercise of pre-funded warrants into common stock (in shares)																		31,521
Exercise of pre-funded warrants into common stock																		$ 3			4,906,627					4,906,630
Deemed dividend on preferred stock exchanges																										(21,008,253)
Dividends on preferred stock																					(349,132)					(349,132)
Common stock and pre-funded warrants issued upon conversion of Series C preferred stock (in shares)																		104,182
Common stock and pre-funded warrants issued upon conversion of Series C preferred stock															$ (3)	(3)	(3)	$ 10			(7)
Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs (in shares)																		54,182
Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs																		$ 6			14,156,044					14,156,050
Effect of cancelled shares from the 10-for-1 reverse stock split (in shares)																		(56)
Issuance of common stock at-the-market for cash, net of offering costs (in shares)																		55,041
Issuance of common stock at-the-market for cash, net of offering costs																		$ 6			8,325,189					8,325,195
Common stock issued for intellectual property acquired, net (in shares)																		(20,800)
Common stock issued for intellectual property acquired, net																		$ 2			3,999,998					4,000,000
Common stock cancelled in connection with acquisition of First Wave Bio, Inc.																		$ (1)			1
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. (in shares)																		(11,097)
Common stock and warrants issued to consultants (in shares)																		3,241
Issuance of common stock in connection with settlement with former investment bank (in shares)																		250
Issuance of common stock in connection with settlement with former investment bank																					94,499					94,499
Common stock and warrants issued to consultants																					1,215,859					1,215,859
Stock-based compensation																					1,268,710					1,268,710
Foreign currency translation adjustment																							(154,561)			(154,561)
Net loss																						(47,365,362)				(47,365,362)
Balance at the end (in shares) at Sep. 30, 2021														676				370,507
Balance at the end at Sep. 30, 2021																		$ 37			137,028,642	(142,731,560)	(1,267,107)			(6,969,988)
Balance at the beginning (in shares) at Jun. 30, 2021														676				275,283
Balance at the beginning at Jun. 30, 2021																		$ 28			120,593,171	(112,330,772)	(1,225,503)			7,036,924
Issuance of Series C preferred stock upon exchange of Series B preferred stock																					(118,089)					(118,089)
Dividends on preferred stock (in shares)															5,639
Common stock and pre-funded warrants issued upon conversion of Series C preferred stock (in shares)																		20,800
Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs (in shares)																		34,848
Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs																		$ 3			5,096,757					5,096,760
Effect of cancelled shares from the 10-for-1 reverse stock split (in shares)																		(56)
Issuance of common stock at-the-market for cash, net of offering costs (in shares)																		50,055
Issuance of common stock at-the-market for cash, net of offering costs																		$ 5			7,150,842					7,150,847
Common stock issued for intellectual property acquired, net (in shares)															(5,639)
Common stock issued for intellectual property acquired, net																		2			3,999,998					4,000,000
Common stock cancelled in connection with acquisition of First Wave Bio, Inc.																		$ (1)			1
Common stock cancelled in connection with acquisition of First Wave Bio, Inc. (in shares)																		(11,096)
Common stock and warrants issued to consultants																					123,548					123,548
Common stock and warrants issued to consultants (in shares)																		673
Stock-based compensation																					182,414					182,414
Foreign currency translation adjustment																							(41,604)			(41,604)
Net loss																						(30,400,788)				(30,400,788)
Balance at the end (in shares) at Sep. 30, 2021														676				370,507
Balance at the end at Sep. 30, 2021																		$ 37			137,028,642	(142,731,560)	(1,267,107)			(6,969,988)
Balance at the beginning (in shares) at Dec. 31, 2021														662				495,194
Balance at the beginning at Dec. 31, 2021																		$ 50			147,306,582	(153,904,047)	(1,224,135)			(7,821,550)
Deemed dividend of Series B preferred stock																					(298,195)					(298,195)
Warrant modification																					47,300					47,300
Deemed dividend on warrant modifications																					(47,300)					(47,300)
Common stock issued upon conversion of Series B preferred stock (in shares)				(150)	33,332			(150)	33,332
Common stock issued upon conversion of Series B preferred stock					$ 3	$ (3)			$ 3	$ (3)
Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)	55,000
Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs	$ 6	$ 7,971,926	$ 7,971,932														$ 150			$ 178,336					$ 178,336
Exercise of pre-funded warrants into common stock (in shares)																		161,606
Exercise of pre-funded warrants into common stock																		$ 16			47,997					48,013
Conversion of Series B preferred shares into common stock (in shares)												(31)	6,374
Effect of cancelled shares from the 10-for-1 reverse stock split (in shares)																		(98)
Issuance of common stock at-the-market for cash, net of offering costs (in shares)																		1,519,257
Issuance of common stock at-the-market for cash, net of offering costs																$ 150		$ 153	$ 20,664		7,691,069			$ 20,664		7,691,222
Common stock and warrants issued to consultants (in shares)																		3,011
Common stock and warrants issued to consultants																					118,990					118,990
Stock-based compensation																					684,778					684,778
Foreign currency translation adjustment																							(230,586)			(230,586)
Net loss																						(10,643,653)				(10,643,653)
Balance at the end (in shares) at Sep. 30, 2022														631				2,307,008
Balance at the end at Sep. 30, 2022																		$ 231			163,722,141	(164,547,700)	(1,454,721)			(2,280,049)
Balance at the beginning (in shares) at Jun. 30, 2022														631				756,660
Balance at the beginning at Jun. 30, 2022																		$ 76			156,168,578	(168,939,031)	(1,419,486)			(14,189,863)
Issuance of Series C preferred stock and warrants for cash, net of offering costs (in shares)				150				150
Issuance of Series C preferred stock and warrants for cash, net of offering costs						178,336	$ 178,336			20,664	$ 20,664
Deemed dividend of Series B preferred stock																					(110,278)					(110,278)
Deemed dividend on warrant modifications																										(47,000)
Common stock issued upon conversion of Series B preferred stock (in shares)				(150)	33,332			(150)	33,332
Common stock issued upon conversion of Series B preferred stock					$ 3	$ (3)			$ 3	$ (3)
Conversion of Series B preferred shares into common stock (in shares)																		(98)
Issuance of common stock at-the-market for cash, net of offering costs (in shares)																		1,483,782
Issuance of common stock at-the-market for cash, net of offering costs																		$ 149			7,373,206					7,373,355
Stock-based compensation																					91,641					91,641
Foreign currency translation adjustment																							(35,235)			(35,235)
Net loss																						4,391,331				4,391,331
Balance at the end (in shares) at Sep. 30, 2022														631				2,307,008
Balance at the end at Sep. 30, 2022																		$ 231			$ 163,722,141	$ (164,547,700)	$ (1,454,721)			$ (2,280,049)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (unaudited) (Parenthetical) - shares			3 Months Ended		9 Months Ended
	Aug. 26, 2022	Sep. 13, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Condensed Consolidated Statements of Changes in Stockholders' Deficit (unaudited)
Reverse stock splits (in shares)	30	10	30	10	30	10

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (10,643,653)	$ (47,365,362)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	21,953	9,390
Amortization		395,661
Change in right-of-use assets	61,681	(4,855)
Change in fair value liability		(532,353)
Stock-based compensation	684,778	1,268,710
Common stock and warrants granted to consultants	118,990	1,310,358
Changes in assets and liabilities:
Other receivables	(191,984)	551,489
Prepaid expenses	614,809	964,310
Lease liabilities	(93,438)	(289,409)
Deposits	9,714	(16,114)
Accounts payable	875,257	2,179,334
Accrued expenses	(120,985)	(282,031)
Payable related to acquisition	(8,085,045)	15,000,000
Other liabilities	(3,867)	385,440
Net cash used in operating activities	(16,751,790)	(26,425,432)
Cash flows from investing activities:
Purchase of property and equipment		(71,448)
Net cash used in investing activities		(71,448)
Cash flows from financing activities:
Proceeds from issuance of preferred stock, net	199,000	7,105,168
Proceeds from issuance of common stock, net	7,971,932	18,156,050
Proceeds from exercise of warrants	48,013	4,906,630
Payment made related to license agreement		(10,250,000)
Payment made related to acquisition	(4,914,955)
Issuance of common stock at-the-market for cash, net of offering costs	7,691,222	8,325,195
Deferred offering costs	(138,684)
Repayments of note payable	(641,236)	(552,405)
Net cash provided by financing activities	10,215,292	27,690,638
Net (decrease) increase in cash and restricted cash	(6,536,498)	1,193,758
Effect of exchange rate changes on cash	(33,668)	(45,254)
Cash, cash equivalents and restricted cash, beginning balance	8,248,684	6,062,141
Cash, cash equivalents and restricted cash, ending balance	1,678,518	7,210,645
Non-cash investing and financing activities:
Deemed dividend on preferred stock issuances		(4,507,125)
Deemed dividend on preferred stock exchanges		(21,008,253)
Deemed dividend on warrant modifications	(47,300)
Accrued dividends on preferred stock	$ (298,195)	(349,132)
Issuance of Series C preferred stock to settle liability related to license agreement		$ 2,467,649

The Company and Basis of Presen

The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
The Company and Basis of Presentation
The Company and Basis of Presentation	Note 1 - The Company and Basis of Presentation The Company First Wave BioPharma, Inc. (“ First Wave GI The Company is currently focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase (formerly MS1819), a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The Company’s adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency (“ EPI CF CP IBD The Company is developing its product candidates for a host of GI diseases where there are significant unmet clinical needs and limited therapeutic options, resulting in painful, life threatening and discomforting consequences for patients. Since its inception, the Company has devoted substantially all its efforts to research and development, business development, and raising capital, and has financed its operations through issuance of common stock, convertible preferred stock, convertible debt, and other debt/equity instruments. Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund clinical trials and operations. The Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the ongoing COVID-19 pandemic impacts the Company’s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its Common Stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Europe, Asia and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects. In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements. In addition, the Company is subject to other challenges and risks specific to its business, its ability to comply with the terms of the extension granted by the Nasdaq hearings panel and to regain compliance with the continued listing requirements of The Nasdaq Capital Market and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the biotechnology and pharmaceutical industries with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its drug candidates; delays or problems in the manufacture and supply of its drug candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or drug candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above. Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP FWB In our opinion, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2021, has been derived from audited financial statements of that date. The unaudited interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes previously distributed in our Annual Report Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022 (as amended on Form 10-K/A filed with the SEC on May 10, 2022). Going Concern Uncertainty The accompanying unaudited interim condensed consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. On September 30, 2022, the Company had cash and cash equivalents of approximately $1.7 million, an accumulated deficit of approximately $164.5 million, and negative working capital of approximately $4.1 million. The Company has incurred recurring losses, has experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. Based on its cash on hand at September 30, 2022, and the approximately $5.2 million in net proceeds received from a follow-on offering that closed on October 11, 2022, the Company anticipates having sufficient cash to fund planned operations into the first quarter of 2023, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for the need to raise additional capital to complete development of its products. Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its capital stock. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without adequate working capital, the Company may not be able to meet its obligations and continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2022
Significant Accounting Policies and Recent Accounting Pronouncements
Significant Accounting Policies and Recent Accounting Pronouncements	Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements Use of Estimates The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill and intangible assets), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates. Reverse Stock Split On August 26, 2022, the Company effected a reverse stock split, whereby every thirty shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, but without any change in the number of authorized shares of common stock and the par value per share. On September 13, 2021, the Company effected a reverse stock split, whereby every ten shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, with a corresponding 1-for-10 reduction in the number of authorized shares of common stock, but without any change in the par value per share. All share and per share amounts have been retroactively restated to reflect the reverse stock splits referenced above. Reclassifications Certain prior period balance sheet amounts have been reclassified to conform to the fiscal 2022 presentation. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with maturities of three months or less from date of purchase to be cash equivalents. All cash balances were highly liquid on September 30, 2022, and December 31, 2021, respectively. As of September 30, 2022 and December 31, 2021, the Company has classified approximately $0.022 million and $0 million, respectively, as restricted cash. Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. On September 30, 2022, and December 31, 2021, the Company had approximately $1.1 million and $7.5 million, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros. Fair Value Measurements The Company follows Accounting Standards Codification ( ASC ( ASC 820 As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period. Foreign Currency Translation The Company’s foreign subsidiary has operations denominated in a foreign currency, and assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity. Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years The carrying amounts of finite-lived intangible assets are evaluated for recoverability whenever events or changes in circumstances indicate that the Company may be unable to recover the asset’s carrying amount. Given changes in the projected usage of the patents, the Company recognized impairment charges Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment ( ASC 360 Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ ROU Research and Development Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third parties for preclinical and non-clinical activities, expenses with clinical research organizations (“ CROs CDMOs CMC Research and Development – The Company records intellectual property in asset acquisitions that have not reached technological feasibility and which have no alternative future use, as an expense at the acquisition date. On December 31, 2020, the Company entered into a license agreement (the “ FWB License Agreement On July 29, 2022, the Company reached an agreement to restructure its obligations to the former FWB stockholders (the “ July 2022 Term Sheet Second Payment Stock-Based Compensation The Company’s board of directors (the “ Board 2014 Plan 2020 Plan ASC 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (the “ FASB SEC In June 2016, the FASB issued accounting pronouncement ASU 2016-13 – Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company does not expect the adoption of this standard to have a material effect on its financial statements and related disclosures . In June 2022, the FASB issued ASU 2022-03 - Fair Value Measurement, or Topic 820: Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, or ASU 2016-13. This new standard clarifies the guidance in Topic 820 when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The Company has assessed the impact of the update and determined it does not have a material impact on the accompanying financial statements and disclosures. The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Fair Value Disclosures

Fair Value Disclosures	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures
Fair Value Disclosures	Note 3 - Fair Value Disclosures Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measured at Reporting Date ​ ​ ​ ​ ​ ​ ​ ​ Using ​ ​ ​ ​ ​ Carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount Level 1 Level 2 Level 3 Fair Value September 30, 2022 (unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 505,179 ​ $ 505,179 ​ $ — ​ $ — ​ $ 505,179 Note payable ​ — ​ — ​ — ​ — ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ ​ 501,607 ​ ​ 501,607 ​ ​ — ​ ​ — ​ ​ 501,607 Note payable ​ $ 641,236 ​ $ — ​ $ 641,236 ​ $ — ​ $ 641,236 ​ At September 30, 2022 and December 31, 2021, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.

Asset Acquisition

Asset Acquisition	9 Months Ended
	Sep. 30, 2022
Asset Acquisition
Asset Acquisition	Note 4 – Asset Acquisition The Asset Acquisition On September 13, 2021, the Company completed its acquisition of FWB, in accordance with the terms of an Agreement and Plan of Merger dated as of September 13, 2021 (the “ Merger Agreement Merger Sub Merger At the effective time of the Merger, the former FWB stockholders received an applicable pro rata share of (i) $3.0 million in cash and (ii) 20,800 shares of the Common Stock (equivalent to cash of $4.0 million). The remaining non-contingent purchase price was payable to the former FWB stockholders on a pro rata basis upon the Company’s payment of (i) $8.0 million in cash, payable within 45 days of the Merger, and (ii) $7.0 million in cash, payable by March 31, 2022 for a total purchase price of $22.0 million. The former FWB stockholders were entitled to up to a total of $207 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals relating to the use of the acquired assets. All milestone payments were payable in cash, provided that 25% of the milestone payments attributable to certain IBD indications could be payable in Common Stock, at the option of the Company. In addition, the former FWB stockholders were entitled to 10% of certain specified revenue received by the Company from any third-party with a pre-existing niclosamide development program relating to COVID. On October 29, 2021, Fortis Advisors LLC, the hired representative (in such capacity, the “ Representative On November 15, 2021, the Company reached an agreement (the “ November 2021 Settlement Agreement During the three and nine months ended September 30, 2022 the Company paid an aggregate of $2.5 million and $4.9 million in cash towards the purchase price. During the year ended December 31, 2021, the Company paid an aggregate of $7.0 million (in cash and shares) towards the purchase price and $2.0 million in milestone payments. On May 19, 2022, the Representative filed a complaint against the Company in the Court of Chancery in the State of Delaware (the “ FWB Action July 2022 Term Sheet Second Payment Payments In the July 2022 Term Sheet, the Representative agreed to stay the FWB Action for a period of 90 days and to eliminate the Company’s obligation to pay a portion of any offering proceeds to the Representative. In addition, the Company’s obligation to use commercially reasonable efforts to develop niclosamide will be deferred for a period of 24 months from the date of the July 2022 Term Sheet. Effective upon the Second Payment, the Representative dismissed the FWB Action with prejudice and extinguished the remaining fixed payment obligations owed to the former FWB shareholders. Accounting Treatment The Company concluded that the Merger should be accounted for as an asset acquisition under ASC 805 because substantially all the fair value of the assets being acquired are concentrated in a single asset - intellectual property, which does not constitute a business. Because the acquired intellectual property has not received regulatory approval, the $21.3 million non-contingent purchase price was immediately expensed in the Company’s statements of operations as research and development – intellectual property acquired in the year ended December 31, 2021. The $0.9 million of transaction expenses paid at closing were classified in general and administrative expenses in the year ended December 31, 2021. The Common Stock issued for the asset acquisition was valued at $4.0 million, which is equal to the 20,800 common shares issued multiplied by $192.30 per share. Under the July 2022 Term Sheet, the $1.5 million in cash due and paid on July 29, 2022, as well as the Second Payment due and paid in September 2022, were recorded as a reduction to current liabilities for the three months ended September 30, 2022. Effective upon the Second Payment, the approximately $10.1 million of remaining fixed payment obligations previously owed to the former FWB shareholders was settled. The remaining payment obligation of $2.0 million due by November 30, 2022 was recorded as research and development expense in the three months ended September 30, 2022. The remaining unachieved potential milestone payments and revenue share are not yet considered probable, therefore have not been accrued as of September 30, 2022. Depending on the status of development at the time a contingent payment is recognized, the Company may determine that the payment should be expensed as research and development or be capitalized as an intangible asset. This determination will be based on the facts and circumstances that exist at the time a contingent payment is recognized.

Property, Equipment and Leaseho

Property, Equipment and Leasehold Improvements	9 Months Ended
	Sep. 30, 2022
Property, Equipment and Leasehold Improvements
Property, Equipment and Leasehold Improvements	Note 5 – Property, Equipment and Leasehold Improvements Property, equipment, and leasehold improvements consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Computer equipment and software ​ $ 11,540 ​ $ 11,540 Office equipment ​ 48,278 ​ 48,278 Leasehold improvements ​ 28,000 ​ 28,000 Total property, plant, and equipment ​ 87,818 ​ 87,818 Less accumulated depreciation ​ (36,661) ​ (14,708) Property, plant and equipment, net ​ $ 51,157 ​ $ 73,110 ​ Depreciation expense for the three months ended September 30, 2022 and 2021 was approximately $7,300 and $6,000, respectively, and for the nine months ended September 30, 2022 and 2021 was approximately $22,000 and $9,000, respectively.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2022
Intangible Assets and Goodwill
Intangible Assets and Goodwill	Note 6 – Intangible Assets and Goodwill Patents Pursuant to the Mayoly asset purchase agreement entered in March 2019 (see Note 12), in which the Company purchased all remaining rights, title and interest in and to adrulipase from Mayoly, the Company recorded Patents in the amount of approximately $3.8 million as follows: ​ ​ ​ ​ ​ Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at December 31, 2019 ​ 449,280 Due to Mayoly at December 31, 2020 ​ 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt ​ 1,219,386 Total Patents ​ $ 3,802,745 ​ Intangible assets are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Patents ​ $ — ​ $ 3,802,745 Less accumulated amortization ​ — ​ (1,450,757) Intangible asset impairment ​ — ​ (2,351,988) Patents, net ​ $ — ​ $ — ​ Amortization expense was approximately $132,000 and $396,000 for the three and nine months ended September 30, 2021, respectively. During the year ended December 31, 2021, the Company recorded impairment charges Goodwill is as follows: ​ ​ ​ ​ ​ ​ Goodwill Balance on January 1, 2021 ​ $ 2,054,048 Foreign currency translation ​ (142,343) Balance on December 31, 2021 ​ 1,911,705 Foreign currency translation ​ (196,918) Balance on September 30, 2022 (unaudited) ​ $ 1,714,787 ​

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Accrued Expenses
Accrued Expenses	Note 7 - Accrued Expenses Accrued expenses consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Professional fees ​ $ 205,932 ​ $ 15,000 Payroll and benefits ​ ​ 40,771 ​ ​ 274,153 Consulting fees ​ ​ 25,565 ​ ​ 104,100 Total accrued expenses ​ $ 272,268 ​ $ 393,253 ​

Note Payable

Note Payable	9 Months Ended
	Sep. 30, 2022
Note Payable
Note Payable	Note 8 – Note Payable Directors and Officer ’ s Liability Insurance On November 30, 2021, the Company entered into a 9-month

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2022
Capital Stock
Capital Stock	Note 9 – Common Stock and Preferred Stock The Company’s certificate of incorporation, as amended and restated on February 14, 2022, (the “ Charter On August 26, 2022, the Company effected a reverse stock split, whereby every thirty shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, but without any change in the number of authorized shares of common stock and the par value per share. On September 13, 2021, the Company effected a reverse stock split, whereby every ten shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, with a corresponding 1-for-10 reduction in the number of authorized shares of common stock, but without any change in the par value per share. All share and per share amounts have been retroactively restated to reflect the reverse stock splits referenced above. The Company had 2,307,008 and 495,194 shares of its Common Stock issued outstanding The Company has designated 5,194.805195 shares as Series B Preferred Stock and had approximately 631.34 and 662.25 shares of Series B preferred stock issued outstanding The Company has designated 57,000 shares as Series C Preferred Stock and had 0 shares of Series C Preferred Stock issued and outstanding on September 30, 2022 and December 31, 2021, respectively. The Company has designated 150 shares as Series D Preferred Stock and had 0 shares of Series D Preferred Stock issued and outstanding on September 30, 2022 and December 31, 2021, respectively. The Company has designated 150 shares as Series E Preferred Stock and had 0 shares of Series E Preferred Stock issued and outstanding on September 30, 2022 and December 31, 2021, respectively. Series B Convertible Preferred Stock Pursuant to the Certificate of Designation of Rights and Preferences of the Series B Preferred Stock (the “ Series B Certificate of Designation Series B Stated Value Series B Preferred Stock Waiver Agreements Between February 1 and February 7, 2022, the Company entered into waiver agreements (the “ Waiver Series B Preferred Stock Pursuant to the Series B Certificate of Designation, in the event of any issuance by the Company or any of its subsidiaries of Common Stock or common stock equivalents for cash consideration or a combination of units thereof (a “ Subsequent Financing Series B Exchange Right During the nine months ended September 30, 2022, the Company entered into Waivers with holders of approximately $2.88 million of stated value of Series B Preferred Stock. The Company also entered into Waivers with Company insiders holding approximately $0.047 million of stated value of Series B Preferred Stock for which the Company did not pay a waiver fee. The cash waivers paid of approximately $0.233 million were recorded as other expense on the Company’s condensed consolidated statements of operations for the nine months ended September 30, 2022. Series B Exchange Right Permanent Waiver Effective May 12, 2022, the holders of 81.3% of the outstanding shares of the Series B Preferred Stock permanently waived for themselves and all other holders of the Series B Preferred Stock the Series B Exchange Right with respect to any Subsequent Financing occurring on or after January 1, 2022 (the “ Permanent Waiver Record Holders Pursuant to the terms of the Series B Certificate of Designation, the written consent of the holders of at least a majority of the Series B Preferred Stock outstanding was required to consent to the Permanent Waiver (the “ Required Consent Expiration Date Consenting Holders The Required Consent was obtained from the Consenting Holders and the solicitation terminated in accordance with its terms as of the Expiration Date. The Permanent Waiver was effective immediately upon the Expiration Date and was binding on all holders of the Series B Preferred Stock, including those holders that did not timely consent to the Permanent Waiver prior to the Expiration Date. The Permanent Waiver will also be applicable to any future holder of Series B Preferred Stock. A notation of the Permanent Waiver was made on the books and records of the Company’s transfer agent and a legend reflecting the Permanent Waiver was placed on any physical share certificate representing shares of Series B Preferred Stock. Pursuant to the terms of a Waiver Agreement entered into by the Company and the Consenting Holders (the “ Waiver Agreement Series B Warrants Exercise Price Reduction Series B Exchanges into the January 2021 Offerings During the nine months ended September 30, 2021, pursuant to the Series B Exchange Right, the Company issued an aggregate of 19,140.14 shares of Series C Preferred Stock and warrants to purchase an aggregate of 63,800 shares of Common Stock in connection with the exchange of approximately 1,839.76 shares of Series B Preferred Stock. The Company analyzed the exchanges pursuant to the Series B Exchange Right from preferred stock to preferred stock qualitatively and determined that the exchanges resulted in a substantive change and should be accounted for as an extinguishment. As such, for the nine months ended September 30, 2021, the Company recognized an aggregate deemed dividend of approximately $21.0 million as calculated by the difference in the carrying value of the Series B Preferred Stock exchanged and the fair value of the Series C Preferred Stock and January 2021 Investor Warrants issued on each exchange date. Equity Line with Lincoln Park In November 2019, the Company entered into a purchase agreement (the “ Equity Line Agreement Lincoln Park Registration Rights Agreement Equity Line Commitment Shares The Company did not issue shares of Common Stock, during either of the three or nine months ended September 30, 2022 and 2021, in connection with the Equity Line Agreement. The Equity Line Agreement expired by its terms on July 31, 2022. At The Market Agreement with H.C. Wainwright On May 26, 2021, the Company entered into an At The Market Offering Agreement (the “ ATM Agreement Wainwright July 2022 Private Placement On July 15, 2022, the Company completed a private placement (the “ July 2022 Offering July 2022 Warrants As compensation to Wainwright, who was the exclusive placement agent in connection with the July 2022 Offering, the Company paid Wainwright a cash fee of 7% of the aggregate gross proceeds raised and reimbursement of certain expenses and legal fees. The Company also issued to designees of Wainwright in a private placement warrants (the “ Placement Agent Warrants During the three months ended September 30, 2022, all of the Series D Preferred Shares and the Series E Preferred Shares were converted into 66,666 shares of Common Stock. March 2022 Registered Direct Offering On March 2, 2022, the Company completed a registered direct offering (the “ March 2022 Offering March 2022 Pre-Funded Warrants March 2022 Warrants March 2022 Placement Agent Warrants The proceeds from the March 2022 Offering were allocated to the Common Stock, Pre-Funded warrants, and March 2022 Investor Warrants based on their relative fair values. The total proceeds of approximately $9.0 million, net of $1.0 million offering costs, were allocated as follows: approximately $2.3 million to the Common Stock, approximately $0.3 million to the Pre-Funded Warrants, and approximately $6.4 million to the March 2022 Warrants. The total offering costs of approximately $1.0 million were recognized in equity. July 2021 Offering On July 22, 2021, the Company entered into an underwriting agreement with Wainwright (the “ July 2021 Offering The Company paid Wainwright an underwriting discount equal to 8.0% of the gross proceeds of the offering, and reimbursed Wainwright for a non-accountable expense allowance of $35,000, $125,000 in legal fees and $15,950 for clearing expenses. Additionally, as partial compensation for Wainwright’s services as underwriter in the offering, the Company issued to Wainwright (or its designees) warrants to purchase 2,437 shares of Common Stock equal to 7.0% of the aggregate number of shares of Common Stock sold in the offering (the “ Wainwright Warrants March 2021 Registered Direct Offering On March 10, 2021, the Company completed a registered direct offering (the “ March 2021 Offering March 2021 Pre-Funded Warrants March 2021 Warrants March 2021 Placement Agent Warrants The proceeds from the March 2021 Offering were allocated to the Common Stock, March 2021 Pre-Funded Warrants, and March 2021 Warrants based on their relative fair values. The total proceeds of approximately $9.1 million, net of $0.9 million offering costs, were allocated as follows: approximately $3.9 million to the Common Stock, approximately $2.6 million to the pre-funded warrants, and approximately $3.5 million to the March 2021 Warrants. The total offering costs of approximately $0.9 million were recognized in equity. Common Stock Issuances Issuances for the Three and Nine Months Ended September 30, 2022 During the three months ended September 30, 2022, the Company issued and sold an aggregate of 1,483,782 shares of Common Stock under the ATM Agreement for which the Company received net proceeds of approximately $7.4 million. During the three months ended September 30, 2022, the Company issued an aggregate of 66,666 shares of Common Stock upon the conversion of Series E During the three months ended September 30, 2022, the Company cancelled an aggregate of 98 shares of Common Stock in connection with the 30-for-1 reverse stock split on August 26, 2022. During the nine months ended September 30, 2022, the Company issued 55,000 shares of Common Stock under the March 2022 Offering for which the Company received net proceeds of approximately $8.0 million. During the nine months ended September 30, 2022, the Company issued an aggregate of 161,606 shares of Common Stock upon the conversion of the March 2022 Pre-Funded Warrants issued at a par value of $0.30 (See Note 10). During the nine months ended September 30, 2022, the Company issued an aggregate of 6,374 shares of Common Stock and accompanying Exchange Warrants upon the exchange of an aggregate of 30.92 shares of Series B Preferred Stock with a stated value of approximately $238,000 plus accrued dividends of approximately $27,000. During the nine months ended September 30, 2022, the Company issued an aggregate of 3,001 shares of its Common Stock to consultants with a grant date fair value of approximately $119,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense. During the nine months ended September 30, 2022, the Company issued and sold an aggregate of 1,519,257 shares of Common Stock under the ATM Agreement for which the Company received net proceeds of approximately $7.7 million. During the nine months ended September 30, 2022, the Company cancelled an aggregate of 98 shares of Common Stock in connection with the 30-for-1 reverse stock split on August 26, 2022. Issuances for the Three and Nine Months Ended September 30, 2021 During the three months ended September 30, 2021, the Company issued an aggregate of 673 shares of its Common Stock to consultants with a grant date fair value of approximately $124,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense. During the three months ended September 30, 2021, the Company issued an aggregate of 34,848 shares of Common Stock in connection with the July 2021 Offering. During the three months ended September 30, 2021, the Company issued an aggregate of 20,800 shares of Common Stock in connection with the FWB Merger and canceled and 11,097 shares of Common Stock held by FWB immediately prior to the FWB Merger, which shares of Common Stock are authorized and unissued (see Note 4). During the three months ended September 30, 2021, the Company cancelled an aggregate of 56 shares of Common Stock in connection with the 10-for-1 reverse stock split on September 13, 2021. During the nine months ended September 30, 2021, the Company issued an aggregate of 3,240 shares of its Common Stock to consultants with a grant date fair value of approximately $1.2 million for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense. During the nine months ended September 30, 2021, the Company issued an aggregate 250 shares of its Common Stock with a grant date fair value of approximately $94,000 in connection with the settlement with the Company’s former investment bank, which was recorded as stock-based compensation and included as part of general and administrative expense. During the nine months ended September 30, 2021, the Company issued an aggregate of 104,182 shares of Common Stock upon the conversion of an aggregate of 33,097.10 shares of Series C Preferred Stock with a stated value of approximately $24.7 million plus accrued dividends of approximately $198,000. During the nine months ended September 30, 2021, the Company issued an aggregate of 31,521 shares of Common Stock upon the exercise of an aggregate of 31,712 investor warrants, including an aggregate of 13,305 pre-funded warrants (See Note 10). During the nine months ended September 30, 2021, the Company issued an aggregate of 8,609 shares of Common Stock upon the conversion of an aggregate of 258.08 shares of Series B Preferred Stock with a stated value of approximately $2.0 million plus accrued dividends of approximately $3,000. During the nine months ended September 30, 2021, the Company issued an aggregate of 54,181 shares of Common Stock in connection with the March 2021 Offering and July 2021 Offering, as detailed below. Series C Purchase Agreement On January 5, 2021, the Company closed on a securities purchase agreement (the “ Series C Purchase Agreement January 2021 Registered Direct Offering Concurrently with the January 2021 Registered Direct Offering, in a private placement offering pursuant to the Series C Purchase Agreement (the “ January 2021 Private Placement January 2021 Investor Warrants The net proceeds to the Company from the offerings described above (the “ January 2021 Offerings The Company also issued warrants to the placement agent (the “ January 2021 Placement Agent Warrants The proceeds from the January 2021 Offerings were allocated to the Series C Preferred Stock and the January 2021 Investor Warrants based on their relative fair values. The total proceeds of approximately $7.1 million, net of $0.9 million offering costs, were allocated as follows: approximately $4.6 million to the Series C Preferred Stock and approximately $3.4 million to the January 2021 Investor Warrants. After allocation of the proceeds, the effective conversion price of the Series C Preferred Stock was determined to be beneficial and, as a result, the Company recorded a deemed dividend of approximately $4.5 million equal to the intrinsic value of the beneficial conversion feature and recognized on the closing date and recorded as a reduction of income available to common stockholders in computing basic and diluted loss per share. The total offering costs of approximately $0.9 million were recognized in equity. During the nine months ended September 30, 2021, all outstanding shares of Series C Preferred Stock were converted to Common Stock.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2022
Warrants
Warrants	Note 10 – Warrant activity for the nine months ended September 30, 2022 and 2021 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise Price ​ Remaining ​ Warrants Per Share Term in Years Outstanding and exercisable on January 1, 2022 183,999 ​ $ 284.70 3.95 Issued 464,245 ​ 20.36 4.49 Expired (4,279) ​ 1,125.78 — Exercised (161,606) ​ 0.30 4.42 Warrants outstanding and exercisable on September 30, 2022 482,359 ​ $ 90.19 4.07 ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding and exercisable on January 1, 2021 83,687 ​ $ 366.00 4.04 Issued 133,114 ​ 233.03 4.11 Expired (1,698) ​ 1,080.16 — Exercised (31,712) ​ 159.32 4.10 Warrants outstanding and exercisable on September 30, 2021 183,391 ​ $ 298.47 4.16 ​ The outstanding warrants expire from 2022 through 2027. In connection with the March 2022 Offering, the Company entered into a warrant amendment agreement with an investor pursuant to which the Company agreed to amend the investor’s existing warrants to purchase up to 35,555 shares of Common Stock at an exercise price of $240.00 per share issued in January 2021 and warrants to purchase up to 13,097 shares of Common stock at an exercise price of $363.00 per share issued in March 2021 (the “ Existing Warrants During the nine months ended September 30, 2022, the Company issued March 2022 Warrants, March 2022 Pre-Funded Warrants, and March 2022 Placement Agent Warrants to purchase 391,205 shares of Common Stock in connection with the March 2022 Offering, Exchange Warrants to purchase 6,374 shares of Common Stock in connection with a Series B Preferred Stock exchange (See Note 9), as well as July 2022 Warrants to purchase 66,666 shares of Common Stock in connection with the July 2022 Offering. During the nine months ended September 30, 2021, the Company issued warrants, pre-funded warrants, and placement agent warrants to purchase 44,486 and 21,789 shares of the Company’s Common Stock in connection with the January 2021 Offerings and the March 2021 Offering, respectively, placement agent warrants to purchase 2,437 shares of the Company’s Common Stock in connection with the July 2021 Offering, warrants to purchase 63,736 shares of the Company’s Common Stock in connection with exchanges made pursuant to the Series B Exchange Right (See Note 9), as well as warrants to purchase 666 shares of Common Stock issued to a consultant.

Equity Incentive Plan

Equity Incentive Plan	9 Months Ended
	Sep. 30, 2022
Equity Incentive Plan
Equity Incentive Plan	Note 11 – Equity Incentive Plan The Company’s Board and stockholders adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan (the “ 2014 Plan The Company’s Board and stockholders adopted and approved the 2020 Omnibus Equity Incentive Plan (the “ 2020 Plan ISOs As of January 1, 2022, the number of shares of Common Stock available for issuance under the 2020 Plan automatically increased to 70,478. As of September 30, 2022, there were an aggregate of 70,478 shares available under the 2020 Plan, of which 22,946 shares were issued and outstanding and 47,532 shares were available for potential issuances. As of September 30, 2022, there were an aggregate of 8,680 shares available under the 2014 Plan, of which 5,012 shares were issued and outstanding and 2,094 shares are reserved subject to issuance of restricted stock and restricted stock unit awards (“ RSUs During the nine months ended September 30, 2022 and 2021, stock option activity under the 2014 Plan and 2020 Plan was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ ​ Number ​ Exercise ​ Contract ​ Intrinsic ​ of Shares Price Life (Years) Value Outstanding at January 1, 2022 13,737 ​ $ 353.73 7.28 ​ $ — Granted 22,938 ​ 41.17 7.50 ​ — Canceled (3,745) ​ 355.14 — ​ — Forfeited ​ (4,972) ​ ​ 120.20 ​ — ​ ​ — Outstanding at September 30, 2022 27,958 ​ $ 138.63 8.45 ​ $ — Exercisable at September 30, 2022 13,740 ​ $ 215.59 7.75 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at January 1, 2021 13,567 ​ $ 373.80 7.94 ​ $ — Granted 5,841 ​ 258.30 10.00 ​ — Canceled (4,482) ​ 314.10 2.87 ​ — Outstanding at September 30, 2021 14,926 ​ $ 346.50 7.57 ​ $ — Exercisable at September 30, 2021 9,342 ​ $ 412.80 6.78 ​ $ — ​ During the nine months ended September 30, 2022 and 2021, the Board approved the grant of options to purchase 22,938 and 5,841 shares of Common Stock, respectively. All option grants were pursuant to the 2020 Plan. In general, options granted under the 2020 Plan vest monthly over a 36-month period. During the nine months ended September 30, 2022 and 2021, stock options to purchase an aggregate of 3,745 and 4,482 shares of Common Stock under the 2020 Plan were cancelled. During the nine months ended September 30, 2022, stock options to purchase 4,972 shares of Common Stock were forfeited. For the nine months ended September 30, 2022 and 2021, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 Contractual term (in years) 6.50 ​ 10.00 ​ Expected Volatility 90.92 % 88.71 % Risk-free interest rate 1.12 % 1.29 % Expected Dividend yield 0 % 0 % ​ Using the Black-Scholes Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of common stock granted during the nine months ended September 30, 2022 and 2021 was $31.96 and $201.24, respectively. As of September 30, 2022, the Company had unrecognized stock-based compensation expense of approximately $0.9 million. Approximately $0.4 million of this unrecognized expense will be recognized over the average remaining vesting term of the stock options of 8.44 years. Approximately $0.5 million of this unrecognized expense will vest upon achieving certain clinical and/or corporate milestones. The Company will recognize the expense related to these milestones when the milestones become probable. As of September 30, 2021, the Company had unrecognized stock-based compensation expense of approximately $1.1 million. Approximately $0.9 million of this unrecognized expense will be recognized over the average remaining vesting term of the stock options of 1.85 years. Approximately $0.3 million of this unrecognized expense will vest upon achieving certain clinical and/or corporate milestones. The Company will recognize the expense related to these milestones when the milestones become probable. As of September 30, 2022 and 2021, the Company had 916 shares of restricted stock that had not yet vested and unrecognized restricted common stock expense of approximately $394,000. Approximately $197,000 of this unrecognized expense vests upon the first commercial sale in the United States of Adrulipase and approximately $197,000 of this unrecognized expense vests upon the total market capitalization of the Company exceeding $1.0 billion for 20 consecutive trading days. These milestones were not considered probable as of September 30, 2022. The total stock-based compensation expense for employees and non-employees is included in the accompanying condensed consolidated statements of operations and as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 2022 2021 Research and development ​ $ 22,623 ​ $ 126,611 ​ $ 93,870 ​ $ 556,688 General and administrative ​ 69,018 ​ 55,803 ​ 590,908 ​ 712,022 Total stock-based compensation expense ​ $ 91,641 ​ $ 182,414 ​ $ 684,778 ​ $ 1,268,710 ​

Agreements

Agreements	9 Months Ended
	Sep. 30, 2022
Agreements
Agreements	Note 12 – Agreements License Agreement with First Wave Bio, Inc. (FWB) On December 31, 2020, the Company entered into the FWB License Agreement, pursuant to which FWB granted us a worldwide, exclusive right to develop, manufacture, and commercialize FWB’s proprietary immediate release and enema formulations of niclosamide (the “ Niclosamide Product In consideration of the license and other rights granted by FWB, the Company agreed to pay FWB a $9.0 million upfront cash payment due within 10 days, which was paid in January 2021, and was obligated to make an additional payment of $1.25 million due on June 30, 2021, which was paid in July 2021. In addition, the Company was obligated to pay potential milestone payments to FWB totaling up to $37.0 million for each indication, based upon the achievement of specified development and regulatory milestones. In September 2021, the Company achieved a milestone related to clinical development of niclosamide in the COVID-19 field and has expensed $1.0 million in research and development. Under the FWB License Agreement, the Company was obligated to pay FWB royalties as a mid-single digit percentage of net sales of the Niclosamide Product, subject to specified reductions. The Company was also obligated to issue to FWB junior convertible preferred stock, initially convertible into $3.0 million worth of Common Stock based upon the volume weighted average price of the Common Stock for the five-day period immediately preceding the date of the FWB License Agreement, or $273.54 per share, convertible into an aggregate of 10,967 shares of Common Stock. On January 8, 2021, the Company entered into a securities purchase agreement with FWB (the “ FWB Purchase Agreement The conversion price of the Series C Preferred Stock was determined to be beneficial and, as a result, the Company recorded a deemed dividend of approximately $230,000 equal to the intrinsic value of the beneficial conversion feature and recognized on the issuance date and recorded as a reduction of income available to common stockholders in computing basic and diluted loss per share. Upon the 2021 Stockholder Approval on February 24, 2021, the Company recognized a change in fair value of approximately $0.5 million based on the difference in fair value of the $3.0 million liability initially recorded pursuant to the FWB License Agreement as of December 31, 2020 and the fair value of approximately $2.5 million of Series C Preferred Stock issued pursuant to the FWB Purchase Agreement to settle the liability. Following the 2021 Stockholder Approval, the shares of Series C Preferred Stock were automatically converted into Common Stock. Upon consummating the Merger on September 13, 2021, the FWB License Agreement was effectively canceled. Mayoly Agreement On March 27, 2019, the Company and Laboratories Mayoly Spinder (“ Mayoly Mayoly APA JDLA

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases
Leases	Note 13 – The Company leases its offices under operating leases which are subject to various rent provisions and escalation clauses. The Company is a party to two real property operating leases for the rental of office space. The Company has office space of 3,472 square feet in Boca Raton, Florida that is used for its corporate headquarters with a term through August 31, 2026. The Company also has office space in in Brooklyn, New York on a month-to-month basis. The Company was previously a party to office space in Hayward, California with a term through May 31, 2022, which was not renewed upon its expiration. The Company’s leases expire at various dates through 2026. The escalation clauses are indeterminable and considered not material and have been excluded from minimum future annual rental payments. Lease expense was approximately $36,000 and $79,000, respectively, for the three months ended September 30, 2022 and 2021 and $115,000 and $186,000, respectively, for the nine months ended September 30, 2022 and 2021. The weighted-average remaining lease term and weighted-average discount rate under operating leases as of September 30, 2022 are: ​ ​ ​ ​ ​ ​ ​ September 30, ​ 2022 Lease term and discount rate ​ Weighted-average remaining lease term (years) 3.9 ​ Weighted-average discount rate 7.00 % ​ Maturities of operating lease liabilities as of September 30, 2022, were as follows: ​ ​ ​ ​ ​ 2022 (remainder of year) $ 20,563 2023 ​ 83,691 2024 ​ 86,202 2025 ​ 88,788 2026 ​ 60,593 Total lease payments ​ 339,837 Less imputed interest ​ (44,148) Present value of lease liabilities ​ $ 295,689 ​

Net Income (Loss) per Common Sh

Net Income (Loss) per Common Share	9 Months Ended
	Sep. 30, 2022
Net Income (Loss) per Common Share
Net Income (Loss) per Common Share	Note 14 - Net Income (Loss) per Common Share Basic net income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible preferred stock that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options, warrants and preferred stock is computed using the treasury stock method. In periods where the Company records a net loss, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive. For the three months ended September 30, 2022, stock options in the amount of 27,958 and warrants in the amount of 482,359 were excluded from the calculation of diluted net income per share as they did not have a dilutive effect. For the three months ended September 30, 2022, convertible preferred stock in the amount of 24,321 shares were included in the calculation of diluted net income per share. ​ Basic and diluted net income (loss) per share was calculated as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Nine Months Ended ​ September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Net income (loss) ​ $ 4,391,331 ​ $ (30,400,788) ​ $ (10,643,653) ​ $ (47,365,362) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted average shares outstanding ​ 1,601,415 ​ 311,411 ​ 952,794 ​ 253,118 Convertible preferred stock ​ 24,321 ​ — ​ — ​ — Diluted weighted average shares outstanding ​ 1,625,736 ​ 311,411 ​ 952,794 ​ 253,118 Basic net income (loss) per share ​ $ 2.64 ​ $ (98.00) ​ $ (11.53) ​ $ (289.31) Diluted net income (loss) per share ​ $ 2.60 ​ $ (98.00) ​ $ (11.53) ​ $ (289.31) ​ All shares of Common Stock that may potentially be issued in the future are as follows: ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 ​ September 30, 2021 ​ (unaudited) (unaudited) Common stock warrants 482,359 183,391 Stock options 27,958 14,926 Convertible preferred stock (1) 24,321 24,045 Total shares of common stock issuable 534,638 222,362 (1) Convertible preferred stock is assumed to be converted at the rate of $231.00 per common share, which is the conversion price as of September 30, 2022 .

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
	Sep. 30, 2022
Employee Benefit Plans
Employee Benefit Plans	Note 15 - Employee Benefit Plans 401(k) Plan Since 2015, the Company has sponsored a multiple employer defined contribution benefit plan, which complies with Section 401(k) of the Internal Revenue Code covering substantially all employees of the Company. All employees are eligible to participate in the plan. Employees may contribute from 1% to 100% of their compensation and the Company matches an amount equal to 100% on the first 6% of the employee contribution and may also make discretionary profit-sharing contributions. Employer contributions under this 401(k) plan amounted to approximately $21,000 and $26,000 for the three months ended September 30, 2022 and 2021, respectively, and approximately $97,000 and $81,000 for the nine months ended September 30, 2022 and 2021, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events
Subsequent Events	Note 16 - Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements except for the item noted below. Dissolution of AzurRx SAS Effective October 26, 2022, AzurRx SAS was dissolved. Public Offering On October 6, 2022, the Company entered into a securities purchase agreement with investors pursuant to which the Company agreed to sell, in a best efforts public offering (the “ October 2022 Offering October 2022 Pre-Funded Warrants October 2022 Warrants The net proceeds of the October 2022 Offering, after deducting the placement agent’s fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the October 2022 Warrants, is $5.2 million. The Company intends to use the net proceeds from the October 2022 Offering to make the final upfront payment owed to the former stockholders of FWB pursuant to the July 2022 Settlement Agreement. The Company intends to use the remaining net proceeds from the October 2022 Offering for working capital and general corporate purposes. The October 2022 Offering closed on October 11, 2022. July 2022 Offering On October 5, 2022, the Company entered into termination agreements with Wainwright to void 4,000 warrant shares issued to Wainwright pursuant to the July 2022 Offering.

Significant Accounting Polici_2

Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2022
Significant Accounting Policies and Recent Accounting Pronouncements
Use of Estimates	Use of Estimates The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill and intangible assets), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.
Reverse Stock Split	Reverse Stock Split On August 26, 2022, the Company effected a reverse stock split, whereby every thirty shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, but without any change in the number of authorized shares of common stock and the par value per share. On September 13, 2021, the Company effected a reverse stock split, whereby every ten shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, with a corresponding 1-for-10 reduction in the number of authorized shares of common stock, but without any change in the par value per share. All share and per share amounts have been retroactively restated to reflect the reverse stock splits referenced above.
Reclassifications	Reclassifications Certain prior period balance sheet amounts have been reclassified to conform to the fiscal 2022 presentation.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with maturities of three months or less from date of purchase to be cash equivalents. All cash balances were highly liquid on September 30, 2022, and December 31, 2021, respectively. As of September 30, 2022 and December 31, 2021, the Company has classified approximately $0.022 million and $0 million, respectively, as restricted cash.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. On September 30, 2022, and December 31, 2021, the Company had approximately $1.1 million and $7.5 million, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros.
Fair Value Measurements	Fair Value Measurements The Company follows Accounting Standards Codification ( ASC ( ASC 820 As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period.
Foreign Currency Translation	Foreign Currency Translation The Company’s foreign subsidiary has operations denominated in a foreign currency, and assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years The carrying amounts of finite-lived intangible assets are evaluated for recoverability whenever events or changes in circumstances indicate that the Company may be unable to recover the asset’s carrying amount. Given changes in the projected usage of the patents, the Company recognized impairment charges
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment ( ASC 360
Leases	Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ ROU
Research and Development	Research and Development Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third parties for preclinical and non-clinical activities, expenses with clinical research organizations (“ CROs CDMOs CMC Research and Development – The Company records intellectual property in asset acquisitions that have not reached technological feasibility and which have no alternative future use, as an expense at the acquisition date. On December 31, 2020, the Company entered into a license agreement (the “ FWB License Agreement On July 29, 2022, the Company reached an agreement to restructure its obligations to the former FWB stockholders (the “ July 2022 Term Sheet Second Payment
Stock-Based Compensation	Stock-Based Compensation The Company’s board of directors (the “ Board 2014 Plan 2020 Plan ASC 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (the “ FASB SEC In June 2016, the FASB issued accounting pronouncement ASU 2016-13 – Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company does not expect the adoption of this standard to have a material effect on its financial statements and related disclosures . In June 2022, the FASB issued ASU 2022-03 - Fair Value Measurement, or Topic 820: Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, or ASU 2016-13. This new standard clarifies the guidance in Topic 820 when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The Company has assessed the impact of the update and determined it does not have a material impact on the accompanying financial statements and disclosures. The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Fair Value Disclosures (Tables)

Fair Value Disclosures (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures
Summary of financial instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measured at Reporting Date ​ ​ ​ ​ ​ ​ ​ ​ Using ​ ​ ​ ​ ​ Carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount Level 1 Level 2 Level 3 Fair Value September 30, 2022 (unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 505,179 ​ $ 505,179 ​ $ — ​ $ — ​ $ 505,179 Note payable ​ — ​ — ​ — ​ — ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ ​ 501,607 ​ ​ 501,607 ​ ​ — ​ ​ — ​ ​ 501,607 Note payable ​ $ 641,236 ​ $ — ​ $ 641,236 ​ $ — ​ $ 641,236

Property, Equipment and Lease_2

Property, Equipment and Leasehold Improvements (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Equipment and Leasehold Improvements
Summary of property, equipment and leasehold improvements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Computer equipment and software ​ $ 11,540 ​ $ 11,540 Office equipment ​ 48,278 ​ 48,278 Leasehold improvements ​ 28,000 ​ 28,000 Total property, plant, and equipment ​ 87,818 ​ 87,818 Less accumulated depreciation ​ (36,661) ​ (14,708) Property, plant and equipment, net ​ $ 51,157 ​ $ 73,110

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2022
Intangible Assets and Goodwill
Schedule of patents	​ ​ ​ ​ ​ Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at December 31, 2019 ​ 449,280 Due to Mayoly at December 31, 2020 ​ 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt ​ 1,219,386 Total Patents ​ $ 3,802,745
Schedule of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Patents ​ $ — ​ $ 3,802,745 Less accumulated amortization ​ — ​ (1,450,757) Intangible asset impairment ​ — ​ (2,351,988) Patents, net ​ $ — ​ $ — ​
Schedule of goodwill	​ ​ ​ ​ ​ ​ Goodwill Balance on January 1, 2021 ​ $ 2,054,048 Foreign currency translation ​ (142,343) Balance on December 31, 2021 ​ 1,911,705 Foreign currency translation ​ (196,918) Balance on September 30, 2022 (unaudited) ​ $ 1,714,787

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Accrued Expenses
Summary of accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Professional fees ​ $ 205,932 ​ $ 15,000 Payroll and benefits ​ ​ 40,771 ​ ​ 274,153 Consulting fees ​ ​ 25,565 ​ ​ 104,100 Total accrued expenses ​ $ 272,268 ​ $ 393,253

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2022
Warrants
Schedule of warrant activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise Price ​ Remaining ​ Warrants Per Share Term in Years Outstanding and exercisable on January 1, 2022 183,999 ​ $ 284.70 3.95 Issued 464,245 ​ 20.36 4.49 Expired (4,279) ​ 1,125.78 — Exercised (161,606) ​ 0.30 4.42 Warrants outstanding and exercisable on September 30, 2022 482,359 ​ $ 90.19 4.07 ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding and exercisable on January 1, 2021 83,687 ​ $ 366.00 4.04 Issued 133,114 ​ 233.03 4.11 Expired (1,698) ​ 1,080.16 — Exercised (31,712) ​ 159.32 4.10 Warrants outstanding and exercisable on September 30, 2021 183,391 ​ $ 298.47 4.16

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2022
Equity Incentive Plan
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ ​ Number ​ Exercise ​ Contract ​ Intrinsic ​ of Shares Price Life (Years) Value Outstanding at January 1, 2022 13,737 ​ $ 353.73 7.28 ​ $ — Granted 22,938 ​ 41.17 7.50 ​ — Canceled (3,745) ​ 355.14 — ​ — Forfeited ​ (4,972) ​ ​ 120.20 ​ — ​ ​ — Outstanding at September 30, 2022 27,958 ​ $ 138.63 8.45 ​ $ — Exercisable at September 30, 2022 13,740 ​ $ 215.59 7.75 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at January 1, 2021 13,567 ​ $ 373.80 7.94 ​ $ — Granted 5,841 ​ 258.30 10.00 ​ — Canceled (4,482) ​ 314.10 2.87 ​ — Outstanding at September 30, 2021 14,926 ​ $ 346.50 7.57 ​ $ — Exercisable at September 30, 2021 9,342 ​ $ 412.80 6.78 ​ $ —
Schedule of option pricing model with the following weighted-average assumptions	​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 Contractual term (in years) 6.50 ​ 10.00 ​ Expected Volatility 90.92 % 88.71 % Risk-free interest rate 1.12 % 1.29 % Expected Dividend yield 0 % 0 %
Schedule of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 2022 2021 Research and development ​ $ 22,623 ​ $ 126,611 ​ $ 93,870 ​ $ 556,688 General and administrative ​ 69,018 ​ 55,803 ​ 590,908 ​ 712,022 Total stock-based compensation expense ​ $ 91,641 ​ $ 182,414 ​ $ 684,778 ​ $ 1,268,710

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
Weighted-average remaining lease term and weighted-average discount rate under operating leases	​ ​ ​ ​ ​ ​ ​ September 30, ​ 2022 Lease term and discount rate ​ Weighted-average remaining lease term (years) 3.9 ​ Weighted-average discount rate 7.00 %
Maturities of operating lease liabilities	Maturities of operating lease liabilities as of September 30, 2022, were as follows: ​ ​ ​ ​ ​ 2022 (remainder of year) $ 20,563 2023 ​ 83,691 2024 ​ 86,202 2025 ​ 88,788 2026 ​ 60,593 Total lease payments ​ 339,837 Less imputed interest ​ (44,148) Present value of lease liabilities ​ $ 295,689

Net Income (Loss) per Common _2

Net Income (Loss) per Common Share (Tables)	9 Months Ended
	Sep. 30, 2022
Net Income (Loss) per Common Share
Schedule of basic and diluted net income (loss) per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Nine Months Ended ​ September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Net income (loss) ​ $ 4,391,331 ​ $ (30,400,788) ​ $ (10,643,653) ​ $ (47,365,362) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic weighted average shares outstanding ​ 1,601,415 ​ 311,411 ​ 952,794 ​ 253,118 Convertible preferred stock ​ 24,321 ​ — ​ — ​ — Diluted weighted average shares outstanding ​ 1,625,736 ​ 311,411 ​ 952,794 ​ 253,118 Basic net income (loss) per share ​ $ 2.64 ​ $ (98.00) ​ $ (11.53) ​ $ (289.31) Diluted net income (loss) per share ​ $ 2.60 ​ $ (98.00) ​ $ (11.53) ​ $ (289.31)
Schedule of Common Stock that may potentially be issued in the future	​ ​ ​ ​ ​ ​ ​ September 30, 2022 ​ September 30, 2021 ​ (unaudited) (unaudited) Common stock warrants 482,359 183,391 Stock options 27,958 14,926 Convertible preferred stock (1) 24,321 24,045 Total shares of common stock issuable 534,638 222,362 (1) Convertible preferred stock is assumed to be converted at the rate of $231.00 per common share, which is the conversion price as of September 30, 2022 .

The Company and Basis of Pres_2

The Company and Basis of Presentation (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
The Company and Basis of Presentation
Cash and cash equivalents	$ 1,657,013	$ 8,248,684
Accumulated deficit	(164,547,700)	$ (153,904,047)
Working capital	4,100,000
Proceeds from issuance of shares	$ 5,200,000

Significant Accounting Polici_3

Significant Accounting Policies and Recent Accounting Pronouncements (Details) - USD ($)										1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2022	Sep. 30, 2022	Sep. 29, 2022	Aug. 26, 2022	Jul. 29, 2022	Jul. 22, 2022	May 19, 2022	Sep. 13, 2021	Dec. 31, 2020	Jul. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Significant accounting policies and recent accounting pronouncements
Number of shares reduced due to reverse stock split				30				10			30	10	30	10
Restricted cash		$ 22,000									$ 22,000		$ 22,000		$ 0
Cash in US banks in excess of FDIC insurance limits		1,100,000									1,100,000		$ 1,100,000		7,500,000
Finite-lived intangible asset, useful life (year)													7 years 2 months 12 days
Intangible asset impairment															$ 2,400,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]															Other Nonoperating Income (Expense)
Asset impairment charges													$ 0
First Wave License Agreement
Significant accounting policies and recent accounting pronouncements
Asset acquisition consideration transferred									$ 13,300,000
Payments to acquire intangible assets									10,300,000
Cash consideration									$ 3,000,000				3,000,000
First Wave Bio Inc [Member]
Significant accounting policies and recent accounting pronouncements
Asset acquisition consideration transferred	$ 2,000,000		$ 1,000,000		$ 1,500,000						2,500,000		$ 4,900,000		$ 7,000,000
Cash consideration								$ 4,000,000		$ 1,500,000
Asset Acquisition, Consideration Transferred, Contingent Consideration							$ 4,000,000
Asset acquisition total purchase price								22,000,000
Payments made								$ 3,000,000
First Wave Bio Inc [Member] | Former Stockholders
Significant accounting policies and recent accounting pronouncements
Initial payment						$ 1,500,000
Second payment			$ 1,000,000
Third payment on completion of one or more qualifying equity offerings	2,000,000
Upfront payment paid		1,500,000
Second payment paid		1,000,000
Extinguishment of remaining fixed payment obligations											$ 10,100,000
Third payment recorded as expense	$ 2,000,000
Payments made		$ 2,500,000

Fair Value Disclosures (Details

Fair Value Disclosures (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair value disclosures
Money market funds	$ 1,657,013	$ 8,248,684
Note payable		641,236
Carrying Amount
Fair value disclosures
Note payable		641,236
Fair Value, Inputs, Level 2
Fair value disclosures
Note payable		641,236
Money Market Funds
Fair value disclosures
Money market funds	505,179	501,607
Money Market Funds | Carrying Amount
Fair value disclosures
Money market funds	505,179	501,607
Money Market Funds | Fair Value, Inputs, Level 1
Fair value disclosures
Money market funds	$ 505,179	$ 501,607

Asset Acquisition (Details)

Asset Acquisition (Details) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

11 Months Ended

12 Months Ended

Nov. 30, 2022

Sep. 30, 2022

Sep. 29, 2022

Jul. 29, 2022

May 19, 2022

Nov. 15, 2021

Oct. 29, 2021

Sep. 13, 2021

Jul. 31, 2022

Sep. 30, 2022

Sep. 30, 2022

Jul. 31, 2023

Dec. 31, 2021

Mar. 02, 2022

Mar. 10, 2021

Shares issued price per share (in dollars per share)

$ 41.25

$ 381.75

First Wave Bio Inc [Member]

Payment to acquire

$ 3,000,000

Asset acquired equity issued (in shares)

20,800

Asset acquisition total purchase price

$ 22,000,000

Asset acquisition consideration transferred liabilities incurred

$ 8,000,000

$ 7,000,000

Maximum term for the payment of purchase price

45 days

Milestone payment

$ 2,000,000

Asset Acquisition, Potential Milestone Payments

$ 10,100,000

$ 10,100,000

10,100,000

$ 2,000,000

Asset acquisition consideration transferred

$ 2,000,000

$ 1,000,000

$ 1,500,000

$ 2,500,000

4,900,000

7,000,000

Cash consideration

$ 4,000,000

$ 1,500,000

Asset acquired equity issued (in shares)

20,800

Shares issued price per share (in dollars per share)

$ 192.30

Asset Acquisition, Consideration Transferred, Contingent Consideration

$ 4,000,000

First Wave Bio Inc [Member] | Research and development

Non-contingent purchase price

21,300,000

First Wave Bio Inc [Member] | General and administrative expense.

Consideration transaction cost

$ 900,000

First Wave Bio Inc [Member] | Former Stockholders

Payment to acquire

$ 2,500,000

Milestone payment

$ 2,000,000

Awarded to other party

$ 8,000,000

First Wave Bio Inc [Member] | Development Achievement Threshold [Member]

Asset Acquisition, Potential Milestone Payments

$ 207,000,000

Percentage of cash milestone payments

25%

First Wave Bio Inc [Member] | Patent Infringement [Member]

Percentage of cash consideration

10%

First Wave Bio Inc [Member] | Settlement Agreement

Milestone payment

$ 2,000,000

Awarded to other party

$ 15,000,000

Percentage of amount on the transactions consummated by the company

10%

Specified amount of transactions for applying percentage

$ 10,000,000

Stock cancelled during period, shares, acquisitions (in shares)

332,913

Payment of periodic installments

$ 500,000

First Wave Bio Inc [Member] | Settlement Agreement | Forecast

Payment of periodic installments

$ 1,000,000

Property, Equipment and Lease_3

Property, Equipment and Leasehold Improvements - Property (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Property, Equipment and Leasehold Improvements
Total property, plant, and equipment	$ 87,818		$ 87,818		$ 87,818
Less accumulated depreciation	(36,661)		(36,661)		(14,708)
Property, plant and equipment, net	51,157		51,157		73,110
Depreciation expense	7,300	$ 6,000	22,000	$ 9,000
Computer equipment and software
Property, Equipment and Leasehold Improvements
Total property, plant, and equipment	11,540		11,540		11,540
Office equipment
Property, Equipment and Leasehold Improvements
Total property, plant, and equipment	48,278		48,278		48,278
Leasehold improvements
Property, Equipment and Leasehold Improvements
Total property, plant, and equipment	$ 28,000		$ 28,000		$ 28,000

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Patents (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2020	Dec. 31, 2019
Patents
Patents	$ 3,802,745
Common stock issued at signing to Mayoly
Patents
Patents			$ 1,740,959
Due to Mayoly
Patents
Patents		$ 393,120	$ 449,280
Assumed Mayoly liabilities and forgiveness of Mayoly debt
Patents
Patents	$ 1,219,386

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Intangible Assets (Details)	Dec. 31, 2021 USD ($)
Intangible Assets and Goodwill
Patents	$ 3,802,745
Less accumulated amortization	(1,450,757)
Intangible asset impairment	$ (2,351,988)

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2021
Intangible Assets and Goodwill
Amortization expense	$ 132,000	$ 396,000
Intangible asset impairment			$ 2,400,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]			Other Nonoperating Income (Expense)

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Goodwill (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Intangible Assets and Goodwill
Balance	$ 1,911,705	$ 2,054,048
Foreign currency translation	(196,918)	(142,343)
Balance	$ 1,714,787	$ 1,911,705

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accrued Expenses
Professional fees	$ 205,932	$ 15,000
Payroll and benefits	25,565	104,100
Consulting fees	40,771	274,153
Total accrued expenses	$ 272,268	$ 393,253

Note Payable (Details)

Note Payable (Details) - USD ($)	Nov. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Note Payable
Note payables		$ 0	$ 641,000
Financing Agreement for Directors and Officer's Liability Insurance
Note Payable
Debt Instrument, term	9 months
Debt Instrument, face amount	$ 957,000
Debt instrument, interest Rate	3.99%
Debt instrument, periodic payment	$ 81,000

Capital Stock (Details)

Capital Stock (Details)												1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 26, 2022 $ / shares shares	Jul. 27, 2022 USD ($) shares	Jul. 22, 2022 USD ($) $ / shares shares	Jul. 15, 2022 USD ($) $ / shares shares	May 12, 2022 $ / shares shares	Mar. 02, 2022 USD ($) $ / shares shares	Feb. 07, 2022 USD ($) $ / shares	Sep. 13, 2021 shares	May 26, 2021 shares	Mar. 10, 2021 USD ($) $ / shares shares	Jan. 06, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jan. 31, 2021 $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) shares	Jul. 31, 2022	Feb. 13, 2022 shares	Nov. 30, 2019 USD ($) shares
Common stock, shares authorized (in shares)														50,000,000		50,000,000		50,000,000			25,000,000
Common stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares designated (in shares)														10,000,000		10,000,000
Preferred stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.0001		$ 0.0001
Number of shares reduced due to reverse stock split	30							10						30	10	30	10
Common stock, shares, issued, total (in shares)														2,307,008		2,307,008		495,194
Common stock, shares, outstanding, ending balance (in shares)														2,307,008		2,307,008		495,194
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares						$ 37.80
Purchase of aggregate common stock														482,359	183,391	482,359	183,391	183,999	83,687
Deemed dividend on warrant modifications | $														$ (47,000)		$ (47,300)
Class of warrant or right, number of securities called by warrants or rights (in shares)						1									666		666
Stock issued during period, value, new issues | $														$ 7,373,355	$ 7,150,847	7,691,222	$ 8,325,195
Proceeds from Issuance of Common Stock | $						$ 8,000,000										7,971,932	$ 18,156,050
Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)						55,000				19,333
Shares issued, price per share (in dollars per share) | $ / shares						$ 41.25				$ 381.75
Warrants and rights outstanding, term (year)						5 years				5 years
Proceeds from Issuance or Sale of Equity, Total | $																$ 5,200,000
Preferred stock, convertible, conversion price (in dollars per share) | $ / shares	$ 4.50
Conversion of stock, shares issued (in shares)															34,848
Canceled														98	56	98
Reverse stock split ratio														30	10	30
Payments of Stock Issuance Costs | $																$ 138,684
Pre-funded warrants to purchase of common stock										6,861
FWB
Conversion of stock, shares issued (in shares)															11,097
Class of Warrant or Rights, Investor and Pre_funded Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares										$ 3
Class of warrant or right, number of securities called by warrants or rights (in shares)										13,097
January 2021 Investor Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares													$ 240
Class of warrant or right, number of securities called by warrants or rights (in shares)													35,555
Proceeds from Issuance or Sale of Equity, Total | $											$ 3,400,000
Series C Warrants
Class of warrant or right, number of securities called by warrants or rights (in shares)						216,606
Pre-Funded Warrant
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares						$ 51.90								$ 0.9		$ 0.9
Class of warrant or right, number of securities called by warrants or rights (in shares)						161,606
Shares issued, price per share (in dollars per share) | $ / shares						$ 41.55
Warrants and rights outstanding, term (year)						5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1
Offering costs | $						$ 2,300,000
Proceeds from Issuance or Sale of Equity, Total | $						$ 300,000
January 2021 Placement Agent Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares															$ 281.25		$ 281.25
Class of warrant or right, number of securities called by warrants or rights (in shares)															2,488		2,488
Shares issued, price per share (in dollars per share) | $ / shares															$ 225		$ 225
Percentage Of Common Stock Issued In Offering																	7%
March 2022 Prefunded Warrants [Member]
Class of warrant or right, number of securities called by warrants or rights (in shares)						1
Proceeds from Issuance or Sale of Equity, Total | $						$ 6,400,000
March 2021 Placement Agent Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares										$ 477.18
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)										1,833
Equity Offering, Price Per Share (in dollars per share) | $ / shares										$ 381.75
Percentage of warrants issued										7%
Percentage of exercise price of warrants										125%
Waiver
Purchase of aggregate common stock					251,742
Waiver | Warrants.
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares					$ 0.25
Series C Preferred Stock Converted into Common Stock
Conversion of Series B preferred shares into common stock (in shares)																	104,182
Conversion of Stock, Shares Converted (in shares)																	33,097.10
Issuance of stock upon conversion of securities | $																	$ 24,700,000
Conversion of Stock, Amount Converted, Accrued Dividends | $																	$ 198,000
Series B Preferred Stock Converted into Common Stock
Conversion of stock, shares issued (in shares)																	8,609
Conversion of Stock, Shares Converted (in shares)																	258.08
Issuance of stock upon conversion of securities | $																	$ 2,000,000
Conversion of Stock, Amount Converted, Accrued Dividends | $																	$ 3,000
Series B Preferred Stock Exchanged for Common Shares
Conversion of Stock, Shares Converted (in shares)																30.92
Issuance of stock upon conversion of securities | $																$ 238,000
Conversion of Stock, Amount Converted, Accrued Dividends | $																$ 27,000
Series B Preferred Stock Exchanged for Common Shares | Series C Warrants
Conversion of stock, shares issued (in shares)																6,374
Consultants [Member]
Stock Issued During Period, Shares, Settlement (in shares)															673	3,001	3,240
Stock Issued During Period, Value, Settlement | $															$ 124,000	$ 119,000	$ 1,200,000
Officers and Directors | Waiver
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares					$ 0.3294
Former Investor Bank
Stock Issued During Period, Value, Settlement | $												$ 94,000
Shares issued for settlement (in shares)																	250
Equity Line Agreement | Lincoln Park
Common stock, shares, issued, total (in shares)																						1,623
Fair value of commitment shares on grant date | $																						$ 297,000
At The Market Offering Agreement
Stock issued during period, value, new issues | $														$ 7,400,000		$ 7,700,000
Stock issued during period, shares, new issues (in shares)														1,483,782		1,519,257
At The Market Offering Agreement | Wainwright
Stock Sales Agreement, Commission on Shares Sold, Percentage									3%
Stock Sales Agreement, Number of Shares Authorized (in shares)									8,000,000
Market Agreement | H C Wainwright Co L L C
Proceeds from Issuance of Common Stock | $														$ 7,700,000	7,400,000	$ 8,000,000	$ 8,600,000
Stock issuance costs | $														$ 293,000	$ 228,000	$ 309,000	$ 274,000
Stock issued during period, shares, new issues (in shares)														1,483,782	50,055	1,519,257	55,040
March 2021 Offering
Proceeds from Issuance or Sale of Equity Net | $																$ 9,100,000
Offering costs | $										$ 900,000
January 2021 offering
Offering costs | $											900,000
Proceeds from Issuance or Sale of Equity, Total | $											7,100,000						$ 7,100,000
March 2022 offering
Stock issued during period, value, new issues | $																$ 8,000,000
Stock issued during period, shares, new issues (in shares)																55,000
Proceeds from Issuance or Sale of Equity Net | $						$ 1,000,000				$ 9,000,000
Offering costs | $																$ 1,000,000
July 2021 offering
Proceeds from Issuance of Common Stock | $		$ 5,100,000
Underwriting option		30 days
Stock issued during period, shares, new issues (in shares)		4,545
July 2021 offering | Wainwright Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares			$ 206.25
Warrants and rights outstanding, term (year)			5 years
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering			125%
July 2021 offering | Wainwright
Class of warrant or right, number of securities called by warrants or rights (in shares)			2,437
Stock issued during period, shares, new issues (in shares)			30,303
Shares issued, price per share (in dollars per share) | $ / shares			$ 165
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering			7%
Non-accountable Expenses | $			$ 35,000
Legal Fees | $			125,000
Clearance Fees | $			$ 15,950
Underwriting discount			8%
Direct offering | Pre-Funded Warrant
Class of warrant or right, number of securities called by warrants or rights (in shares)						12,996								2.6		2.6
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering						6%										3.50%
Private Placement
Class of warrant or right, number of securities called by warrants or rights (in shares)				4,000
Gross proceeds from private placement | $				$ 300,000
Percentage of cash fees paid to placement agent				7%
Warrant
Class of warrant or right, exercised during period (in shares)																	31,712
Pre-Funded Warrants
Shares issued, price per share (in dollars per share) | $ / shares														$ 0.30		$ 0.30
Conversion of stock, shares issued (in shares)																161,606
Class of warrant or right, exercised during period (in shares)																	13,305
Series B Preferred Stock
Preferred stock, shares designated (in shares)														5,194.805195		5,194.805195		5,194.805195
Preferred stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares issued, total (in shares)														631.34		631.34		662.25
Preferred stock, stated value per share (in dollars per share) | $ / shares														$ 7,700		$ 7,700
Preferred stock, dividend rate, percentage																			9%
Aggregate dividends payable | $																$ 764,000		$ 465,000
Class of warrant or right, number of securities called by warrants or rights (in shares)															63,736		63,736
Conversion of Series B preferred shares into common stock (in shares)																	1,839.76
Preferred stock, dividends, payment of fractional shares amount | $																			$ 100
Preferred stock, shares outstanding (in shares)														631.34		631.34		662.25
Series B Preferred Stock | Waiver
Preferred stock, par or stated value per share (in dollars per share) | $ / shares							$ 0.0001
Cash waiver fee (in percentage)							10%
Preferred stock, alternate redemption value | $							$ 7,700
Value of preferred stock agreed to be waived with holders of preferred stock | $														$ 2,880,000		$ 2,880,000
Value of preferred stock agreed to be waived with insiders | $							$ 47,000
Waiver fee paid | $																$ 233,000
Percentage of outstanding shares					81.30%
Series C Preferred Stock
Preferred stock, shares designated (in shares)														57,000		57,000		57,000
Preferred stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares issued, total (in shares)														0		0		0
Convertible preferred stock, shares issued upon conversion (in shares)															19,140.14		19,140.14
Class of warrant or right, number of securities called by warrants or rights (in shares)															63,800		63,800
Deemed dividends on preferred stock issuances | $											4,500,000						$ 21,000,000
Proceeds from Issuance or Sale of Equity, Total | $											$ 4,600,000
Preferred stock, shares outstanding (in shares)														0		0		0
Series C Preferred Stock | January 2021 Placement Agent Warrants
Percentage of effective purchase price per share of preferred stock																	125%
Series C Preferred Stock | January 2021 Registered Direct Offering
Convertible preferred stock, shares issued upon conversion (in shares)															17,777		17,777
Stock issued during period, shares, new issues (in shares)																	5,333.33
Shares issued, price per share (in dollars per share) | $ / shares															$ 750		$ 750
Preferred stock, convertible, conversion price (in dollars per share) | $ / shares															$ 225		$ 225
Series C Preferred Stock | January 2021 Private Placement
Stock issued during period, shares, new issues (in shares)													5,333.33
Series C Preferred Stock | Private Placement
Number of common shares issuable upon conversion				33,333
Series D Preferred Stock
Preferred stock, shares designated (in shares)														150		150		150
Preferred stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares issued, total (in shares)														0		0		0
Conversion of stock, shares issued (in shares)														66,666
Preferred stock, shares outstanding (in shares)														0		0		0
Series D Preferred Stock | Private Placement
Number of shares reduced due to reverse stock split				33,333
Preferred stock, stated value per share (in dollars per share) | $ / shares				$ 1,000
Number of common shares issuable upon conversion														66,666		66,666
Convertible preferred stock, shares issued upon conversion (in shares)				66,666
Stock issued during period, shares, new issues (in shares)				150
Preferred stock, convertible, conversion price (in dollars per share) | $ / shares				$ 4.50
Series E Preferred Stock
Preferred stock, shares designated (in shares)														150		150		150
Preferred stock, par or stated value per share (in dollars per share) | $ / shares														$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares issued, total (in shares)														0		0		0
Conversion of stock, shares issued (in shares)														66,666
Preferred stock, shares outstanding (in shares)														0		0		0
Series E Preferred Stock | Private Placement
Preferred stock, par or stated value per share (in dollars per share) | $ / shares				$ 1,000
Number of shares reduced due to reverse stock split	33,333
Number of common shares issuable upon conversion				33,333
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares				$ 4.50
Stock issued during period, shares, new issues (in shares)				150
Warrants and rights outstanding, term (year)																				5 years
Common Stock
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares										$ 363
Stock Issued During Period, Shares, Exercise of Warrants (in shares)															20,800		31,521
Common Stock | Pre-Funded Warrant
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares						$ 0.30								$ 3.9		$ 3.9
March 2021 and July 2021 Offering
Stock issued during period, shares, new issues (in shares)																	54,181
Maximum | Equity Line Agreement | Lincoln Park
Issuance of available Equity Line Agreement | $																						$ 15,000,000

Warrants (Details)

Warrants (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Mar. 02, 2022	Mar. 31, 2021	Mar. 10, 2021	Jan. 31, 2021
Number of Warrants
Warrants outstanding and exercisable, beginning (in shares)	183,999	83,687	83,687
Issued (in shares)	464,245	133,114
Expired (in shares)	(4,279)	(1,698)
Exercised (in shares)	(161,606)	(31,712)
Warrants outstanding and exercisable, ending (in shares)	482,359	183,391	183,999	83,687
Weighted Average Exercise Price Per Share
Warrants outstanding and exercisable, beginning (in dollars per share)	$ 284.70	$ 366	$ 366
Issued (in dollars per share)	20.36	233.03
Expired (in dollars per share)	1,125.78	1,080.16
Exercised (in dollars per share)	0.30	159.32
Warrants outstanding and exercisable, ending (in dollars per share)	$ 90.19	$ 298.47	$ 284.70	$ 366
Weighted Average Remaining Term in Years
Outstanding and exercisable (in years)	4 years 25 days	4 years 1 month 28 days	3 years 11 months 12 days	4 years 14 days
Issued (in years)	4 years 5 months 26 days	4 years 1 month 9 days
Exercised (in years)	4 years 5 months 1 day	4 years 1 month 6 days
Warrants to purchase of stock		666				1
Warrant exercise price						$ 37.80
Shares issued, price per share (in dollars per share)						$ 41.25		$ 381.75
Warrant amendment agreement
Weighted Average Remaining Term in Years
Warrant exercise price					$ 0.8430		$ 363		$ 240
Consideration for purchase of securities					$ 9
March Offering [Member]
Weighted Average Remaining Term in Years
Shares issued, price per share (in dollars per share)					$ 37.80
Maximum | Warrant amendment agreement
Weighted Average Remaining Term in Years
Warrants to purchase of stock							13,097		35,555

Warrant - Series B, Pre-funded

Warrant - Series B, Pre-funded and Placement agent Warrants (Details) - $ / shares	Sep. 30, 2022	Mar. 02, 2022	Sep. 30, 2021
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock		1	666
Warrant exercise price		$ 37.80
Series B preferred stock
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock			63,736
July 2022 offering
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock	66,666
July 2022 offering | Series B preferred stock
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock	6,374
Warrants, pre-funded warrants, and placement agent warrants | January 2021 offering
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock			44,486
Warrants, pre-funded warrants, and placement agent warrants | March 2021 offering
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock			21,789
Warrants, pre-funded warrants, and placement agent warrants | March 2022 offering
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock	391,205
Warrants, pre-funded warrants, and placement agent warrants | July 2021 offering
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock			2,437

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional information (Details)		3 Months Ended		9 Months Ended		21 Months Ended
	Sep. 11, 2020 shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Jan. 01, 2022 shares
Equity Incentive Plan
Granted				22,938	5,841
Options cancelled		98	56	98
Unrecognized stock-based compensation expense | $		$ 900,000	$ 1,100,000	$ 900,000	$ 1,100,000	$ 900,000
First commercial sale in the United States of Adrulipase
Equity Incentive Plan
Unrecognized expense vests | $				197,000	197,000
Vesting Over Remaining Term
Equity Incentive Plan
Unrecognized stock-based compensation expense | $		400,000	900,000	$ 400,000	$ 900,000	$ 400,000
Average remaining vesting term of the stock options (in years)				8 years 5 months 8 days	1 year 10 months 6 days
Vests upon total market capitalization exceeding one million
Equity Incentive Plan
Consecutive trading days | $						20
Unrecognized expense vests | $				$ 197,000	$ 197,000
Vests upon total market capitalization exceeding one million | Maximum
Equity Incentive Plan
Unrecognized stock-based compensation expense | $		1,000,000,000	1,000,000,000	1,000,000,000	1,000,000,000	$ 1,000,000,000
Clinical, corporate milestones
Equity Incentive Plan
Unrecognized stock-based compensation expense | $		500,000	300,000	$ 500,000	$ 300,000	500,000
Incentive Stock Options
Equity Incentive Plan
Granted				50,000
Restricted Stock
Equity Incentive Plan
Vested during the period (in shares)				916	916
Restricted Stock | Common Stock
Equity Incentive Plan
Unrecognized stock-based compensation expense | $		$ 394,000	$ 394,000	$ 394,000	$ 394,000	$ 394,000
Stock Option
Equity Incentive Plan
Weighted average fair value of warrants granted (in dollars per share) | $ / shares				$ 31.96	$ 201.24
2020 Equity Incentive Plan
Equity Incentive Plan
Shares available under equity incentive plan (in shares)	33,333						70,478
Percentage of common stock reserved for issuance equity incentive plan	10%
Shares reserved subject to issuance (in shares)		47,532		47,532		47,532
Options to purchase shares of common stock (in shares)		22,946		22,946		22,946
Vesting period				36 months
Options cancelled				3,745	4,482
Options forfeited				4,972
Equity Incentive Plan2014
Equity Incentive Plan
Shares available under equity incentive plan (in shares)		8,680		8,680		8,680
Options to purchase shares of common stock (in shares)		5,012		5,012		5,012
The 2014 Omnibus Equity Incentive Plan | Restricted Stock
Equity Incentive Plan
Shares reserved subject to issuance (in shares)		2,094		2,094		2,094

Equity Incentive Plan - Stock o

Equity Incentive Plan - Stock option activity (Details) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Numbers of Shares
Granted (in shares)			22,938	5,841
Canceled (in shares)	(98)	(56)	(98)
Incentive Stock Options
Numbers of Shares
Granted (in shares)			50,000
Equity Incentive Plan 2014 And Plan 2020 | Incentive Stock Options
Numbers of Shares
Outstanding at beginning (in shares)			13,737	13,567	13,567
Granted (in shares)			22,938	5,841
Canceled (in shares)			(3,745)
Forfeited (in shares)			(4,972)	(4,482)
Outstanding at ending (in shares)	27,958	14,926	27,958	14,926	13,737	13,567
Exercisable (in shares)	13,740	9,342	13,740	9,342
Average Exercise Price
Outstanding at beginning (in dollars per share)			$ 353.73	$ 373.80	$ 373.80
Granted (in dollars per share)			41.17	258.30
Canceled (in dollars per share)			355.14
Forfeited (in dollars per share)			120.20	314.10
Outstanding at ending (in dollars per share)	$ 138.63	$ 346.50	138.63	346.50	$ 353.73	$ 373.80
Exercisable (in dollars per share)	$ 215.59	$ 412.80	$ 215.59	$ 412.80
Remaining Contract Life (Years)
Stock option outstanding, remaining contractual life (Years)			8 years 5 months 12 days	7 years 6 months 25 days	7 years 3 months 10 days	7 years 11 months 8 days
Granted (in years)			7 years 6 months	10 years
Canceled (in years)			0 years
Forfeited (in years)			0 years	2 years 10 months 13 days
Exercisable (in years)			7 years 9 months	6 years 9 months 10 days

Equity Incentive Plan - Weighte

Equity Incentive Plan - Weighted-average assumptions (Details) - Stock Option	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Contractual term (in years)	6 years 6 months	10 years
Expected Volatility	90.92%	88.71%
Risk-free interest rate	1.12%	1.29%
Expected Dividend yield	0%	0%

Equity Incentive Plan - Total s

Equity Incentive Plan - Total stock-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Equity Incentive Plan
Total stock-based compensation expense	$ 91,641	$ 182,414	$ 684,778	$ 1,268,710
Research and development
Equity Incentive Plan
Total stock-based compensation expense	22,623	126,611	93,870	556,688
General and administrative expense.
Equity Incentive Plan
Total stock-based compensation expense	$ 69,018	$ 55,803	$ 590,908	$ 712,022

Agreements (Details)

Agreements (Details) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Feb. 24, 2021

Jan. 08, 2021

Dec. 31, 2020

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Dec. 31, 2020

Aug. 26, 2022

Mar. 02, 2022

Jun. 30, 2021

Mar. 10, 2021

Agreements

Research and development expense, total

$ 791,067

$ 3,052,791

$ 8,674,480

$ 11,216,616

Preferred stock, convertible, conversion price (in dollars per share)

$ 4.50

Shares issued, price per share (in dollars per share)

$ 41.25

$ 381.75

Fair value, option, changes in fair value, gain (loss)

$ 532,353

Series C Preferred Stock

Agreements

Convertible preferred stock, shares issued upon conversion (in shares)

19,140.14

19,140.14

19,140.14

Series C Preferred Stock | First Wave Purchase Agreement

Agreements

Deemed dividends on preferred stock issuances

$ 230,000

First Wave License Agreement

Agreements

Upfront cash payment to be paid in first ten days

$ 9,000,000

$ 9,000,000

Upfront cash payment term

10 days

Asset acquisition, additional cash to be paid

$ 1,250,000

Asset acquisition, contingent consideration, liability, total

$ 37,000,000

37,000,000

Research and development expense, total

$ 1,000,000

Asset acquisition, consideration transferred, equity interest issued and issuable

3,000,000

$ 3,000,000

Period for conversion of common stock

5 days

Fair value, option, changes in fair value, gain (loss)

$ 500,000

Convertible preferred stock, nonredeemable or redeemable, issuer option, value

3,000,000

$ 3,000,000

Redeemable noncontrolling interest, equity, common, fair value

$ 2,500,000

$ 2,500,000

First Wave License Agreement | Convertible Preferred Stock

Agreements

Preferred stock, convertible, conversion price (in dollars per share)

$ 273.54

$ 273.54

Convertible preferred stock, shares issued upon conversion (in shares)

10,967

10,967

First Wave License Agreement | Series C Preferred Stock

Agreements

Preferred stock, convertible, conversion price (in dollars per share)

$ 225

Convertible preferred stock, shares issued upon conversion (in shares)

10,967

Stock issued during period, shares, new issues (in shares)

3,290.1960

Shares issued, price per share (in dollars per share)

$ 750

Leases (Details)

Leases (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) ft² property	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) ft² property	Sep. 30, 2021 USD ($)
Leases [Line Items]
Number of real property operating leases | property	2		2
Operating lease, expense | $	$ 36,000	$ 79,000	$ 115,000	$ 186,000
Boca Raton, Florida
Leases [Line Items]
Area of real estate property (Square Foot) | ft²	3,472		3,472

Leases - Weighted-average remai

Leases - Weighted-average remaining lease term (Details)	Sep. 30, 2022
Leases
Weighted-average remaining lease term (years)	3 years 10 months 24 days
Weighted-average discount rate	7%

Leases - Maturities of operatin

Leases - Maturities of operating lease liabilities (Details)	Sep. 30, 2022 USD ($)
Leases
2022 (remainder of year)	$ 20,563
2023	83,691
2024	86,202
2025	88,788
2026	60,593
Total lease payments	339,837
Less imputed interest	(44,148)
Present value of lease liabilities	$ 295,689

Net Income (Loss) per Common _3

Net Income (Loss) per Common Share - Basic and diluted net income (loss) per share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net income (loss)	$ 4,391,331	$ (30,400,788)	$ (10,643,653)	$ (47,365,362)
Basic weighted average shares outstanding	1,601,415	311,411	952,794	253,118
Shares of common stock issuable			534,638	222,362
Diluted weighted average shares outstanding	1,625,736	311,411	952,794	253,118
Basic net income (loss) per share	$ 2.64	$ (98)	$ (11.53)	$ (289.31)
Diluted net income (loss) per share	$ 2.60	$ (98)	$ (11.53)	$ (289.31)
Convertible preferred stock
Shares of common stock issuable	24,321		24,321	24,045

Net Income (Loss) per Common _4

Net Income (Loss) per Common Share - Common Stock that may potentially be issued (Details) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Aug. 26, 2022
Net Income (Loss) per Common Share
Total shares of common stock issuable		534,638	222,362
Preferred stock, convertible, conversion price (in dollars per share)				$ 4.50
Common stock warrants
Net Income (Loss) per Common Share
Total shares of common stock issuable		482,359	183,391
Stock options
Net Income (Loss) per Common Share
Total shares of common stock issuable		27,958	14,926
Convertible preferred stock
Net Income (Loss) per Common Share
Total shares of common stock issuable	24,321	24,321	24,045
Preferred stock, convertible, conversion price (in dollars per share)	$ 231	$ 231

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Employee Benefit Plans
Defined contribution plan, employers matching contribution, annual vesting percentage			6%
Defined benefit plan, plan assets, contributions by employer	$ 21,000	$ 26,000	$ 97,000	$ 81,000
Minimum
Employee Benefit Plans
Defined contribution plan, maximum annual contributions per employee, percent			1%
Maximum
Employee Benefit Plans
Defined contribution plan, maximum annual contributions per employee, percent			100%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended	9 Months Ended
	Oct. 06, 2022	Jul. 15, 2022	Sep. 30, 2022	Sep. 30, 2022	Oct. 05, 2022	Jul. 31, 2022	Mar. 02, 2022	Mar. 10, 2021
Subsequent Event [Line Items]
Warrant exercise price							$ 37.80
Warrants term							5 years	5 years
At The Market Offering Agreement
Subsequent Event [Line Items]
Stock issued during period, shares, new issues (in shares)			1,483,782	1,519,257
Series D Preferred Stock | Private Placement
Subsequent Event [Line Items]
Stock issued during period, shares, new issues (in shares)		150
Series E Preferred Stock | Private Placement
Subsequent Event [Line Items]
Stock issued during period, shares, new issues (in shares)		150
Warrant exercise price		$ 4.50
Warrants term						5 years
Subsequent Event | October 2022 Offering
Subsequent Event [Line Items]
Stock issued during period, shares, new issues (in shares)	255,000
Proceeds from issuance of warrants	$ 5.2
Subsequent Event | October 2022 Pre-Funded Warrants
Subsequent Event [Line Items]
Stock issued during period, shares, new issues (in shares)	3,183,396
Warrant exercise price	$ 0.0001
Warrant to purchase of shares	1
Share price	$ 1.7449
Subsequent Event | October 2022 Warrants
Subsequent Event [Line Items]
Stock issued during period, shares, new issues (in shares)	3,438,396
Warrant exercise price	$ 1.62
Warrant to purchase of shares	1
Share price	$ 1.745
Warrants term	5 years
Subsequent Event | July 2022 Offerings
Subsequent Event [Line Items]
Warrant to purchase of shares					4,000